2024 has been off to a great start at HealthXL, with topics ranging from Tech Enabled Change in Oncology Workflows to a Masterclass: The Legacy of Pear Therapeutics

2024 has been off to a great start at HealthXL, with topics ranging from How to Scale Partnerships Between Lifesciences and Digital Health Companies? to Real World Data in Clinical Trials: Benefits and Best Practices.

Many of you may still be relishing in the holiday bliss, but for HealthXL, the new year is already in full swing. Before we properly close the door on last year, I wanted to take a minute (or so …) to reflect on the tumultuous year that has been.

As the year draws to a close so does our AI spotlight series. The series catered to many different interests with topics and conversations focused on themes such as Does AI Guarantee ROI and Revolutionising Pharma: AI's Impact on the Value Chain. 

The HealthXL community convened in Princeton, New Jersey. In collaboration with Otsuka, HealthXL organised its fourth Global Gathering of the year around the theme of Leveraging Data-Driven Strategies for Improving Patient Experience.

By embracing digital measures, pharma can accelerate drug development and improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.

It's been another month of great events at HealthXL, with topics ranging from Enhancing Patient Experiences with Data-Driven Insights to PDT 2.0: The Future of Prescription Digital Therapeutics. To make sure you don't miss the top insights from our community meetings, here are my top five takeaways.

In a recent masterclass, the discussion revolved around approaches, scalability, and accessibility of digital health solutions in GLP-1 medication and obesity management. In this article, we highlight the key insights shared during the session.

‍Introducing new technologies into healthcare settings can be challenging. For example, outdated systems, such as paper-based processes for imaging, can hinder the adoption of new digital health solutions. The medical field can improve treatment and care by deploying new technologies. Additionally e

It's been another month of great events at HealthXL, with topics ranging from Pharma 3.0 and how to do digital health better, to the role medical affairs in the age of digitalisation. Here are my top six takeaways from HealthXL meetings that took place over the past two months.

Few would argue that medical affairs plays a strategic role for digital health in pharma, despite their strategic positioning between commercial and R&D. This new report reevaluates the role of medical affairs in pharma and asks what may be holding them back from a greater role in digital health.

The HealthXL team has returned to Dublin from Gothenburg following yet another successful Global Gathering, this time in collaboration with AstraZeneca. The resounding consensus on the day was that tech in clinical trials will work. 

It's been another month of great events at HealthXL, with topics ranging from ‘DTx Reimbursement: Navigating Medicare & Medicaid Coverage’ to ‘Quantifying the Benefits of Digital Biomarkers in Pharma’.

In recent years, medical affairs has slowly been brought into the digital era with the introduction of tracking tools and new virtual channels for communication with health care practitioners HCPs. Patients' needs and expectations are also changing rapidly.

This month, experts from the HealthXL community led meetings on topics ranging from accounting for cultural differences in digital mental health services to reducing financial toxicity in oncology. In this article, Tess gives her top five meeting takeaways from July.

As AI reshapes the landscape of healthcare and life sciences, keeping abreast of emerging trends, breakthrough technologies, and innovative applications has become crucial. To help you stay ahead of the curve, we're thrilled to launch our "AI in Healthcare and Life Sciences Community".

Pride month has come around again. Companies' logos are more colourful, and what were once protests for equal rights have become parades and celebrations in many parts of the world. Yet, LGBTQIA+ communities still face discrimination within many facets of life; especially when accessing healthcare.

It's been another month of great events at HealthXL. Our Boston Global Gathering was a roaring success. We also hosted many virtual roundtables and masterclasses on a number of topics. Additionally, we ran a great webinar on what pharma and MedTech can learn from each other in digital health.

HealthXL held its second Global Gathering of the year, in collaboration with Takeda, around the theme of Pharma 3.0: The Next Frontier of Digital Health. The event gathered senior leaders from across the pharmaceutical, MedTech and digital health industries, as well as investors and academics.

Our HealthXL meetings in April covered everything from ‘Data Monetisation for MedTech Companies’ to ‘The Potential of OTC DTx Solutions’. To make sure you’re not missing out on the top insights from our communities, and get a sneak peak at some of the conversations, here are my top five takeaways.

Our HealthXL meetings in March covered everything from ‘Navigating the DiGA Framework’ to ‘Leveraging Sources of US Government Funding for Digital Health’. Make sure you’re not missing out on the topics that matter the most to our communities and are plugged into the conversation.